Cargando…

Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro

Administration of cetuximab (C-mab) in combination with paclitaxel (PTX) has been used for patients with head and neck squamous cell carcinoma (SCC) clinically. In this study, we attempted to clarify the molecular mechanisms of the enhancing anticancer effect of C-mab combined with PTX on oral SCC c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawatani, Yuta, Komiyama, Yuske, Nakashiro, Koh-ichi, Uchida, Daisuke, Fukumoto, Chonji, Shimura, Michiko, Hasegawa, Tomonori, Kamimura, Ryouta, Hitomi-Koide, Masayo, Hyodo, Toshiki, Kawamata, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503545/
https://www.ncbi.nlm.nih.gov/pubmed/32878053
http://dx.doi.org/10.3390/ijms21176292
_version_ 1783584418726674432
author Sawatani, Yuta
Komiyama, Yuske
Nakashiro, Koh-ichi
Uchida, Daisuke
Fukumoto, Chonji
Shimura, Michiko
Hasegawa, Tomonori
Kamimura, Ryouta
Hitomi-Koide, Masayo
Hyodo, Toshiki
Kawamata, Hitoshi
author_facet Sawatani, Yuta
Komiyama, Yuske
Nakashiro, Koh-ichi
Uchida, Daisuke
Fukumoto, Chonji
Shimura, Michiko
Hasegawa, Tomonori
Kamimura, Ryouta
Hitomi-Koide, Masayo
Hyodo, Toshiki
Kawamata, Hitoshi
author_sort Sawatani, Yuta
collection PubMed
description Administration of cetuximab (C-mab) in combination with paclitaxel (PTX) has been used for patients with head and neck squamous cell carcinoma (SCC) clinically. In this study, we attempted to clarify the molecular mechanisms of the enhancing anticancer effect of C-mab combined with PTX on oral SCC cells in vitro. We used two oral SCC cells (HSC4, OSC19) and A431 cells. PTX alone inhibited cell growth in all cells in a concentration-dependent manner. C-mab alone inhibited the growth of A431 and OSC19 cells at low concentrations, but inhibited the growth of HSC4 cells very weakly, even at high concentrations. A combined effect of the two drugs was moderate on A431 cells, but slight on HSC4 and OSC19 cells. A low concentration of PTX enhanced the antibody-dependent cellular cytotoxicity (ADCC) induced by C-mab in all of the cells tested. PTX slightly enhanced the anticancer effect of C-mab in this ADCC model on A431 and HSC4 cells, and markedly enhanced the anticancer effect of C-mab on OSC19 cells. These results indicated that PTX potentiated the anticancer effect of C-mab through enhancing the ADCC in oral SCC cells.
format Online
Article
Text
id pubmed-7503545
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75035452020-09-23 Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro Sawatani, Yuta Komiyama, Yuske Nakashiro, Koh-ichi Uchida, Daisuke Fukumoto, Chonji Shimura, Michiko Hasegawa, Tomonori Kamimura, Ryouta Hitomi-Koide, Masayo Hyodo, Toshiki Kawamata, Hitoshi Int J Mol Sci Article Administration of cetuximab (C-mab) in combination with paclitaxel (PTX) has been used for patients with head and neck squamous cell carcinoma (SCC) clinically. In this study, we attempted to clarify the molecular mechanisms of the enhancing anticancer effect of C-mab combined with PTX on oral SCC cells in vitro. We used two oral SCC cells (HSC4, OSC19) and A431 cells. PTX alone inhibited cell growth in all cells in a concentration-dependent manner. C-mab alone inhibited the growth of A431 and OSC19 cells at low concentrations, but inhibited the growth of HSC4 cells very weakly, even at high concentrations. A combined effect of the two drugs was moderate on A431 cells, but slight on HSC4 and OSC19 cells. A low concentration of PTX enhanced the antibody-dependent cellular cytotoxicity (ADCC) induced by C-mab in all of the cells tested. PTX slightly enhanced the anticancer effect of C-mab in this ADCC model on A431 and HSC4 cells, and markedly enhanced the anticancer effect of C-mab on OSC19 cells. These results indicated that PTX potentiated the anticancer effect of C-mab through enhancing the ADCC in oral SCC cells. MDPI 2020-08-31 /pmc/articles/PMC7503545/ /pubmed/32878053 http://dx.doi.org/10.3390/ijms21176292 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sawatani, Yuta
Komiyama, Yuske
Nakashiro, Koh-ichi
Uchida, Daisuke
Fukumoto, Chonji
Shimura, Michiko
Hasegawa, Tomonori
Kamimura, Ryouta
Hitomi-Koide, Masayo
Hyodo, Toshiki
Kawamata, Hitoshi
Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro
title Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro
title_full Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro
title_fullStr Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro
title_full_unstemmed Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro
title_short Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro
title_sort paclitaxel potentiates the anticancer effect of cetuximab by enhancing antibody-dependent cellular cytotoxicity on oral squamous cell carcinoma cells in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503545/
https://www.ncbi.nlm.nih.gov/pubmed/32878053
http://dx.doi.org/10.3390/ijms21176292
work_keys_str_mv AT sawataniyuta paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro
AT komiyamayuske paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro
AT nakashirokohichi paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro
AT uchidadaisuke paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro
AT fukumotochonji paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro
AT shimuramichiko paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro
AT hasegawatomonori paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro
AT kamimuraryouta paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro
AT hitomikoidemasayo paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro
AT hyodotoshiki paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro
AT kawamatahitoshi paclitaxelpotentiatestheanticancereffectofcetuximabbyenhancingantibodydependentcellularcytotoxicityonoralsquamouscellcarcinomacellsinvitro